The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Pinealon

Pinealon · EDR · Glu-Asp-Arg · H-Glu-Asp-Arg-OH

C
Animal replicated
BioregulatorBioregulatorTripeptideNeuroprotective Peptide
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Pinealon is a synthetic Khavinson bioregulator tripeptide with the sequence Glu-Asp-Arg (EDR), positioned for brain and pineal-gland gene-expression support.
Why people use it
Cognitive aging support; circadian rhythm support; neuroprotection hypothesis
What the evidence supports
No Pinealon-specific human RCTs were identified in the site corpus. The public evidence base is primarily Khavinson-associated animal and mechanistic work plus extrapolation from the broader bioregulator program.
Key risks
Single-institution evidence, no modern human RCTs, unknown human PK, uncertain long-term CNS effects
If you only read one thing

Pinealon is one of the more interesting Khavinson Cytogens because the target story is easy to understand: a defined three-amino-acid peptide aimed at brain/pineal gene regulation, with preclinical neuroprotection data and heavy community interest. The evidence gap is just as clear: no modern independent human RCTs, no Western pharmacokinetic characterization, and most claims trace back to the Khavinson research ecosystem.

Check interactions →
Published literature
0human trials0human studies1animal2in vitro

Counts are conservative and Pinealon-specific. Broader Khavinson/Cytogen class evidence and Cytomax clinical-program data are not counted as Pinealon human trials.

Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
3 lab signals
1 animal; 2 in-vitro/mechanistic.
Best-supported use
Neuroprotection / ischemia-reperfusion model
C grade · Low to moderate. Preclinical and primarily Khavinson-associated; not a human efficacy dataset.
Indication map
Supported / plausible / speculative / avoid
Supported
Neuroprotection / ischemia-reperfusion model
C grade · Low to moderate. Preclinical and primarily Khavinson-associated; not a human efficacy dataset.
Supported
Cognitive aging / circadian support
C-D grade · Low. Mechanism is plausible within the bioregulator framework but not independently validated in controlled human trials.

Pinealon belongs on the site because it is a distinct, searchable Khavinson bioregulator with real community use and enough preclinical rationale to merit coverage. It was absent because the existing site had Pinealon embedded inside the broader Khavinson bioregulator pages rather than broken out as its own compound page.

The final editorial position should stay conservative: Pinealon is an EDR brain/pineal tripeptide with a plausible but not independently proven gene-regulatory mechanism. It may be interesting for cognitive longevity and circadian-support protocols, but it does not have modern human RCT validation and should not display a human-evidence badge.

Categories
Cognition & MoodSleep & RecoveryLongevity & Anti-aging
Properties
Active malignancy: cautionSingle-lab provenanceInjectable: extrapolated
Molecular weight
~390 Da
Discovery
Khavinson Cytogen series; synthetic tripeptide associated with brain/pineal bioregulation
Half-life
Unknown in humans; short peptide, likely rapid systemic clearance
Typical dose
Community protocols commonly cite 2 mg daily for 10 days; evidence is extrapolated
Route
SubQ or IM injection in community protocols
Evidence
CAnimal replicated
Key risks
Single-institution evidence, no modern human RCTs, unknown human PK, uncertain long-term CNS effects
Last reviewed
May 2026
Sequence
Glu-Asp-Arg (EDR), a three-amino-acid Cytogen peptide.
Evidence boundary
Do not treat broader Epitalon, Cortexin, or Cytomax evidence as Pinealon-specific human proof.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Epitalon
C
Same class · Bioregulator

40 Years of Research From One Lab. The Most Cited Telomere Peptide in the Longevity Space. The First Independent Replication Was Published in 2025.

Khavinson Bioregulator Cluster
C
Same class · Bioregulator

Four Organ-Specific Bioregulators from the Russian Khavinson Research Tradition. The Theory That Short Peptides Regulate Gene Expression in a Tissue-Specific Way. Cortexin: A Russian-Approved Neuroprotective Extract with Multi-Receptor Activity. CardioCytogen (Ala-Glu-Asp-Arg): The Cardiac Fibroblast Modulator. Crystagen: Connective Tissue and Cartilage Bioregulator. Bronchogen: Pulmonary Bioregulator Tetrapeptide. The Shared Evidence Architecture That Applies to All Four.

Khavinson Bioregulators
C
Same class · Bioregulator

40+ Years of Russian Research. 500+ Publications. One Institution. The Most Concentrated Single-Lab Provenance of Any Compound Class in this reference. Vladimir Khavinson (1946-2024) and the St. Petersburg Institute of Bioregulation and Gerontology. The Epigenetic Chromatin Mechanism. The Cytomax vs Cytogen Distinction. The 6-to-8-Year Mortality Study. The 2025 Independent Replication That Changed the Evidence Conversation. 14 Organ-Specific Bioregulators — Their Sequences, Targets, Evidence, and Protocols.

Check interactions